2024 ATS Onsite Highlights - 22

SCHEDULE AT A GLANCE
INDUSTRY EVENTS
MONDAY, MAY 20
11:30 a.m.-12 p.m.
Asthma Drivers of Disease: the effects of
IL-5 on eosinophils and other cell types that
contribute to airway remodeling and disease
progression
GSK
Innovation Theater 1
11:35-11:55 a.m.
Bronchoscopic Lung Volume Reduction:
High Volume Community Hospital
Perspective with Jason Stienecker, DO
Olympus America Inc.
Innovation Hub 1
11:30 a.m.-12:15 p.m.
New Insights Into Triple Therapy for COPD: A
Focus on the Latest Real-World Evidence
GSK
Innovation Theater 3
11:35-11:55 a.m.
Treating hyperinflammation as an unmet
need in CAP: Investigational agent reparixin
and the REPAVID-22 trial
Dompe
Innovation Hub 3
11:55 a.m.-12:15 p.m.
Earlier Assessment of Uncontrolled Moderate-to-Severe
Asthma. Is There More We Can Do?
sanofi | regeneron
Innovation Hub 2
12-12:30 p.m.
Guidance on Mitigating the Risk of
Transmitting Respiratory Infections During
Nebulization by the COPD Foundation
Nebulizer Consortium
Theravance Biopharma US, Inc
Innovation Theater 2
12:30-1 p.m.
Choose Wisely: ACT™ or AIRQ®?
AstraZeneca
Innovation Theater 1
1-1:30 p.m.
Breathing Innovation: Inhaled Pirfenidone
for the Treatment of Progressive
Pulmonary Fibrosis
Avalyn Pharma
Innovation Theater 2
1:15-1:35 p.m.
The Role of Single-Use Bronchoscopes in
the Bronch Lab with Sonali Sethi, MD
Olympus America Inc.
Innovation Hub 2
6:30-8:00 p.m.
An Expert Panel on Severe Asthma: From the
Epithelium to Better Patient Outcomes
Integras Communications
Hilton Bayfront - Indigo Ballroom
6:30-9:30 p.m.
Pulmonary Arterial Hypertension Gameshow
MedScape
Hilton Bayfront - Sapphire Ballroom
11:30 a.m.-12:30 p.m.
Interstitial Lung Disease:
Presentation to Patient Experience
Boehringer Ingelheim
Pharmaceuticals, Inc.
Innovation Theater 5
11:45 a.m.-12:30 p.m.
AIRSUPRA® (albuterol 90 mcg/
budesonide 80 mcg): A Paradigm Shift
AstraZeneca
Innovation Theater 4
11:55 a.m.-12:15 p.m.
The heterogeneity of COPD pathophysiology and the role of PDE
inhibition: focus on bronchoconstriction
Verona Pharma Inc
Innovation Hub 4
12:15-12:35 p.m.
Veterans in Crisis: Uncovering the Realities
of Burn Pit Exposure and DRRD
4D Medical
Innovation Hub 1
12:35-12:55 p.m.
Ambulation and Long-Term Oxygen Therapy
Inogen
Innovation Hub 2
1-1:45 p.m.
Understanding the Pathophysiology and
Burden of COPD With Blood Eosinophils as
a Marker of T2 Inflammation - Is it the Time
for Precision Medicine in COPD?
GSK
Innovation Theater 3
1:15-1:35 p.m.
The Healthcare of Today, Looking towards
Tomorrow: Digital Innovations and
Patient-Centricity
ResMed
Innovation Hub 4
6:30-9:30 p.m.
Exploring the Impact of OFEV® (nintedanib)
capsules
Boehringer Ingelheim Pharmaceuticals, Inc.
Marriott Marquis - Marina Ballroom F/G
12:15-12:35 p.m.
VERITAS RCT: Has bronchoscopy finally
replaced CT-Guided biopsy?
Medtronic
Innovation Hub 3
12:55-1:15 p.m.
Incidental Findings: Identifying
cancers earlier
Softek Illuminate
Innovation Hub 1
1-2 p.m.
Clinical Considerations for Sleep
Specialists on the Improvement
of Wakefulness in Patients With
Excessive Daytime Sleepiness
Axsome Therapeutics, Inc.
Innovation Theater 5
1:15-2 p.m.
COPD and Asthma with Type 2
Inflammation: Distinct Diseases with
a Shared Cause
sanofi | regeneron
Innovation Theater 4
6:30-9:30 p.m.
Applying Newer Diagnostic and
Therapeutic Tools to the Management
of the Individual with Nontuberculous
Mycobacterial Lung Disease
An Educational Grant from Insmed
Manchester Grand Hyatt - Grand Hall
6:30-9:30 p.m.
Type 2 Inflammation in the Pathophysiology of Asthma and
COPD: What Is It and How Does It Impact Patients?
sanofi | regeneron
Manchester Grand Hyatt - Seaport Ballroom
22
ATS 2024 International Conference
2024 ATS Onsite Highlights

Table of Contents for the Digital Edition of 2024 ATS Onsite Highlights
